Marker Therapeutics Shares Rise Premarket on Key FDA Designation

By Colin Kellaher

Shares of Marker Therapeutics Inc. rose more than 10% in premarket trading Thursday after the clinical-stage immuno-oncology company said the U.S. Food and Drug Administration granted orphan-drug designation to its MT-601 T-cell therapy for the treatment of pancreatic cancer.

The FDA's orphan-drug program gives special status to drugs and biologics for diseases and disorders that affect fewer than 200,000 people in the U.S. and provides for an extended marketing-exclusivity period against competition.

Houston-based Marker said MT-601 is its second multi-antigen targeted T-cell therapy to receive the designation, and its first in a solid tumor indication.

Marker shares, which closed Wednesday at 84 cents, were recently up 11.7% to 94 cents in premarket trading.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

January 20, 2022 06:36 ET (11:36 GMT)

Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Mar 2024 to Apr 2024